{"classes":[{"categories":[{"measurements":[{"comment":"Not reached. Only less than 50% of the patients had events in the Pediatric cohort.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not reached. Only less than 50% of the patients had events in the Adult cohort.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"Duration of response is defined as the time in months between the first instance of response that is subsequently confirmed, until the date of radiographic disease progression or death, whichever occurs first. For participants who enter the LTFU Phase, all MRI assessments in both the Treatment Phase and LTFU Phase will be used to determine duration of response. Participants without radiographic disease progression or death while on study will have their results censored to their most recent adequate (i.e. evaluable) tumor assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients aged 2 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG000","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901)"},{"description":"Patients aged 18 and above at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG001","title":"Treatment Phase - Adult Cohort Mirdametinib (PD-0325901)"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set patients with confirmed objective response.","reportingStatus":"POSTED","timeFrame":"Starting on the onset of confirmed objective response in the Treatment Phase and afterwards on the 15th day of every 4 cycles (each cycle is 28 days) until disease progression or death, whichever comes first, assessed up to approximately 3 years","title":"Duration of Response (DOR) for Participants Who Meet Criteria for Confirmed Objective Response.","type":"SECONDARY","unitOfMeasure":"months"}